Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Penicillamine

Criteria

Inclusion Criteria:

• Be a patient with a confirmed diagnosis of cystinuria.

• Be already taking a CBTD (either D-penicillamine (Cuprimine®) or tiopronin (Thiola®) as part of your medication regimen.

• Be between 18 and 80 years of age

• Be enrolled in the Cystinuria Registry.

Exclusion Criteria:

• You are not a patient with cystinuria

• You are not already taking a cystine binding thiol drug

• You have renal colic (if you are passing a stone)

• You are scheduled to undergo a urologic procedure

• You are unwilling or unable to provide informed consent in order to be able to participate.